Connor, Clark & Lunn Investment Management (CC&L)
XFOR icon

Connor, Clark & Lunn Investment Management (CC&L)’s X4 Pharmaceuticals XFOR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-769
Closed -$39K – 1449
2022
Q3 		$39K Buy
+769
New +$26.6K ﹤0.01% 1070
2022
Q1 		– Sell
-426
Closed -$29K – 1240
2021
Q4 		$29K Buy
+426
New +$53.9K ﹤0.01% 1051

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s XFOR Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of X4 Pharmaceuticals (XFOR) in Q4 2022, closing a stake of 769 shares — an estimated $39K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in XFOR in Q4 2021 and held it in 2 quarters. The position peaked at $39K in Q3 2022. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining X4 Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 769 X4 Pharmaceuticals shares in Q4 2022, an estimated $39K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in X4 Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s X4 Pharmaceuticals position peaked at $39K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.